ATRA-BA Hybrid T35629
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mg | 1037543-26-2 | ¥560.00 | 询底价 |
10 mg | 1037543-26-2 | ¥4,250.00 | 询底价 |
5 mg | 1037543-26-2 | ¥2,430.00 | 询底价 |
Product Introduction
Bioactivity
英文名: ATRA-BA Hybrid
描述: ATRA-BA hybrid is a mutual prodrug form of all-transretinoic acid and butyric acid .1ATRA-BA hybrid is cleaved to release ATRA and BA in isolated mouse plasma. It inhibits the growth of MDA-MB-231 breast and PC3 prostate cancer cells with GI50values of 0.01 and 1.02 μM, respectively. ATRA-BA (20 μM) has 15-fold greater antiproliferative activity in PC3 cells compared to an equimolar concentration of ATRA and BA.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 5 mg/mL
关键字: ATRA-BA Hybrid | ATRABA Hybrid | ATRA BA Hybrid
ATRA-BA Hybrid T35629信息由TargetMol中国为您提供,如您想了解更多关于ATRA-BA Hybrid T35629报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途